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Abstract
Neuroinflammation and oxidative stress underlie the pathogenesis of various neurodegenerative disorders. Here we
demonstrate that sodium phenylbutyrate (NaPB), an FDA-approved therapy for reducing plasma ammonia and glutamine in
urea cycle disorders, can suppress both proinflammatory molecules and reactive oxygen species (ROS) in activated glial
cells. Interestingly, NaPB also decreased the level of cholesterol but involved only intermediates, not the end product of
cholesterol biosynthesis pathway for these functions. While inhibitors of both geranylgeranyl transferase (GGTI) and farnesyl
transferase (FTI) inhibited the activation of NF-kB, inhibitor of GGTI, but not FTI, suppressed the production of ROS.
Accordingly, a dominant-negative mutant of p21
rac, but not p21
ras, attenuated the production of ROS from activated
microglia. Inhibition of both p21
ras and p21
rac activation by NaPB in microglial cells suggests that NaPB exerts anti-
inflammatory and antioxidative effects via inhibition of these small G proteins. Consistently, we found activation of both
p21
ras and p21
rac in vivo in the substantia nigra of acute 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model
of Parkinson’s disease. Oral administration of NaPB reduced nigral activation of p21
ras and p21
rac, protected nigral reduced
glutathione, attenuated nigral activation of NF-kB, inhibited nigral expression of proinflammatory molecules, and
suppressed nigral activation of glial cells. These findings paralleled dopaminergic neuronal protection, normalized striatal
neurotransmitters, and improved motor functions in MPTP-intoxicated mice. Consistently, FTI and GGTI also protected
nigrostriata in MPTP-intoxicated mice. Furthermore, NaPB also halted the disease progression in a chronic MPTP mouse
model. These results identify novel mode of action of NaPB and suggest that NaPB may be of therapeutic benefit for
neurodegenerative disorders.
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Introduction
Neurodegenerative disorders are a group of devastating
disorders of the central nervous system, in which progressive
loss of structure and function of neurons, including neuronal
death is observed. With the progress of research, many
similarities are appearing that ultimately relate these diseases to
one another on a subcellular level. For example, recent studies
demonstrate that neuroinflammation and oxidative stress are two
hallmarks of various neurodegenerative disorders [1,2]. In
neurodegenerative disorders, microglial activation is in close
proximity to damaged or dying dopaminergic neurons. Among
various mediators capable of promoting neurodegeneration are
microglial-derived reactive oxygen species (ROS) and a signifi-
cant source of ROS under such pathological conditions is
NADPH-oxidase, which is a multimeric enzyme composed of
gp91
phox, p22
phox, p47
phox, p67
phox, and p40
phox subunits [3]. It
has been demonstrated that either gp91
phox inactivation [4] or a
chemical inhibitor of NADPH oxidase [5] protects neurons in
various models of neurodegenerative disorders. In addition to
ROS, the concentration of NO2
2 (nitrite), a metabolite of nitric
oxide (NO), increases in the CSF of patients with Parkinson’s
disease and Alzheimer’s disease in comparison age-matched
controls. Similarly, a variety of pro-inflammatory cytokines
including tumor necrosis factor alpha (TNF-a), interleukin-1beta
(IL-1b), IL-6, eicosanoids, and other immune neurotoxins are
found in either CSF or affected brain regions in neurodegener-
ative disorders [6]. Therefore, inflammation and oxidative stress
are important targets for neuronal protection in neurodegener-
ative disorders.
Sodium phenylbutyrate (NaPB) is a FDA-approved drug against
urea cycle disorders in human. Here we delineate new beneficial
properties of NaPB. Interestingly, NaPB suppressed the activation
of NF-kB, inhibited the expression of proinflammatory molecules
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via modulation of the mevalonate pathway and associated
activation of small G proteins like p21
ras and p21
rac. We also
demonstrate that oral administration of NaPB inhibited nigral
activation of p21
ras and p21
rac, suppressed nigral expression of
proinflammatory molecules, improved the level of master antiox-
idant GSH, and exhibited significant protection of the nigrostriatal
axis after MPTP intoxication. These results provide new modes of
action of NaPB and open an option for treating patients with
neurodegenerative disorders with this FDA-approved drug as
primary or adjunct therapy.
Materials and Methods
Animal maintaining and experiments were in accordance with
National Institute of Health guidelines and were approved by the
Institutional Animal Care and Use committee (IACUC#06-048)
of the Rush University of Medical Center, Chicago, IL.
Isolation of Mouse Microglia
Microglia were isolated from mixed glial cultures according to
the procedure of Giulian and Baker [7] with modifications as
previously described [8,9]. Briefly, on day 7–9, the mixed glial
cultures were washed three times with Dulbecco’s modified Eagle’s
medium/F-12 and subjected to shaking at 240 rpm for 2 h at
37uC on a rotary shaker. The floating cells were washed and
seeded on to plastic tissue culture flasks and incubated at 37uC for
1 h. The attached cells were seeded onto new plates for further
studies. Ninety to ninety-five percent of cells were found to be
positive for Mac-1. Mouse BV-2 microglial cells (kind gift from
Virginia Bocchini of University of Perugia) were also maintained
and induced as indicated above.
Isolation of Primary Human Astroglia
Primary human astroglia were prepared as previously described
[10,11,12]. Fetal brain tissues were obtained from the Human
Embryology Laboratory (University of Washington, Seattle, WA,
USA). Briefly, 11- to 17-week-old fetal brains were dissociated by
trituration and trypsinization. On 9
th day, these mixed glial
cultures were placed on a rotary shaker at 240 rpm at 37uC for 2 h
to remove loosely attached microglia. Then on 11
th day, flasks
were shaken again at 190 rpm at 37uC for 18 h to remove
oligodendroglia. The attached cells remaining were primarily
astrocytes. These cells were trypsinized and subcultured to yield
more viable and healthy cells. More than 98% of these cells
obtained by this method were positive for glial fibrillary acidic
protein (GFAP), an astrocyte marker.
Immunoblot Analysis
Immunoblot analysis was carried out as described earlier
[13,14]. Briefly, cells homogenates were electrophoresed, proteins
were transferred onto a nitrocellulose membrane, and protein
band was visualized with Odyssey infrared scanner after
immunolabeling with primary antibodies followed by infra-red
fluorophore-tagged secondary antibody (Invitrogen, Carlsbad,
CA).
Electrophoretic Mobility Shift Assay (EMSA)
Nuclear extracts were prepared and EMSA was carried out as
previously described [9,10,15]. Briefly, IRDye
TM infrared dye
end-labeled oligonucleotides containing the consensus binding
sequence for NF-kB( 5 9-AGT TGA GGG GAC TTT CCC AGG
C-39) were purchased from LI-COR Biosciences (Lincoln, NE).
Six-micrograms of nuclear extract was incubated with binding
buffer and with IR-labeled probe for 20 min. Subsequently,
samples were separated on a 6% polyacrylamide gel in 0.25x TBE
buffer (Tris borate-EDTA) and analyzed by Odyssey Infrared
Imaging System (LI-COR Biosciences).
Transcriptional Activity of NF-kB
Transcriptional activity of NF-kB was assayed as previously
described [9,10,15]. Briefly, cells plated at 50 to 60% confluence in
12-well plates were transfected with 0.25 mg pBIIX-Luc (an NF-
kB-dependent reporter construct) and 12.5 ng pRL-TK (a plasmid
encoding Renilla luciferase, used as transfection efficiency control;
Promega, Madison, WI) using LipofectAMINE Plus (Invitrogen,
Carlsbad, CA). After 24 h of transfection, cells were stimulated
with MPP
+ for an additional 6 h, and firefly and Renilla luciferase
activities were recorded in a TD-20/20 Luminometer (Turner
Designs, Sunnyvale, CA) by analyzing total cell extract according
to standard instructions provided in the Dual Luciferase Kit
(Promega). Relative luciferase activity of cell extracts was typically
represented as (firefly luciferase value/Renilla luciferase value) 6
10
23.
Chromatin Immunoprecipitation (ChIP)
ChIP assays were performed as described earlier [9] using a
ChIP assay kit (Upstate Biotechnology, Lake Placid, NY).
Briefly, 2610
6 microglial cells preincubated with gemfibrozil
for 6 h were stimulated with LPS. After 3 h of stimulation, cells
were fixed by adding formaldehyde (1% final concentration),
and cross-linked adducts were resuspended and sonicated,
resulting in an average chromatin fragment size of 400 bp.
ChIP was performed on the cell lysate by overnight incubation
at 4uC with 2 mg of antibodies against p65 followed by
incubation with protein G agarose (Santa Cruz Biotechnology)
for 2 h. The beads were washed and incubated with elution
buffer. To reverse the cross-linking and purify the DNA,
precipitates were incubated in a 65uC incubator overnight and
digested with proteinase K. DNA samples were then purified,
precipitated, and precipitates were washed with 75% ethanol,
air-dried, and resuspended in TE buffer. Following primers
were used to amplify fragments flanking proximal NF-kB
elements in the mouse iNOS promoter:
Sense: 59-CAT GAG GAT ACA CCA CAG AG-39.
Antisense: 59-AAG ACC CAA GCG TGA GGA GC-39.
Following primers were used to amplify fragments flanking
distal NF-kB elements in the mouse iNOS promoter:
Sense: TGC TAG GGG GAT TTT CCC TCT CTC-39.
Antisense: 59-ACC CTG TTC TGA GAA ACA AA-39.
Sense: 59-GAT GTG CTA GGG GGA TTT TCC C-39.
Antisense: 59-TGG GCT AGC CTG GTC TAC AGA G-39.
The PCRs were repeated by using varying cycle numbers and
different amounts of templates in order to ensure that results were
in the linear range of PCR.
Monitoring Microglial ROS Production
Cells, cultured in 8-well chamber slides, were treated with
MPP
+ under serum-free condition. At different time points of
stimulation, supernatants were removed and cells were washed
with Hank’s buffered salt solution (HBSS) followed by addition of
100 mlo f2 5mM carboxy-H2DCFDA to each well for 30 min of
incubation as described by us [16]. During the last five minutes of
incubation, Hoechst 33342 was added to each well at a dilution of
1:1000 for staining nuclei. Cells were then washed with HBSS,
mounted with DPX mounting media and observed under an
Olympus IX81 fluorescent microscope.
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Superoxide production was detected by LumiMax
TM Superox-
ide Anion Detection Kit (Stratagene) as described by us [30].
Assay of Cholesterol in Serum
Total cholesterol was quantified in serum by using an Amplex
Red Cholesterol Assay kit from Invitrogen. Briefly, cholesterol was
oxidized by cholesterol oxidase to yield H2O2, which then reacted
with 10-acetyl-3,7 dihydroxyphenoxazine (Amplex Red). In the
presence of horseradish peroxidase (HRP), this Amplex Red:H2O2
complex produced highly fluorescent resorufin, which was
detected by fluorometry.
Animals and MPTP Intoxications
Six- to eight-week old C57BL/6 mice were purchased from
Harlan, Indianapolis, IN. For acute MPTP intoxication, mice
received four intraperitoneal (i.p.) injections of MPTP-HCl
(18 mg/kg of free base; Sigma Chemical Co., St. Louis, MO) in
saline at 2 hr intervals [9,17]. Control animals received only
saline. For chronic MPTP intoxication, mice received 10 injections
of MPTP (s.c.; 25 mg/kg body weight) together with 10 injections
of probenecid (i.p.; 250 mg/kg body weight) at an interval of 3.5 d
[18,19].
Drugs and Antibodies
NaPB, farnesyl transferase inhibitor (FTI), geranylgeranyl
transferase inhibitor (GGTI), and rabbit anti-mouse iNOS were
obtained from Calbiochem, Gibbstown, NJ. Rabbit and goat anti-
NF-kB p65 and goat anti-glial fibrillary acidic protein (GFAP)
were purchased from Santa Cruz Biotechnology (Santa Cruz, CA).
Rat anti-mouse CD11b and mouse anti-human CD11b were
purchased from Abcam (Cambridge, MA) and Serotec (Raleigh,
NC), respectively. Cy2- and Cy5-conjugated antibodies were
obtained from Jackson Immuno Research Laboratories (West
Grove, PA).
Drug Treatments
NaPB is a FDA-approved drug for patients with urea cycle
disorders and its recommended dose for affected children is 400–
600 mg/kg/day. However, because either PD patients or MPTP-
intoxicated mice do not suffer from urea cycle disorders, we have
reduced the dose for treating mice. Therefore, for short-term
treatment, mice with acute MPTP intoxication received NaPB
(200 mg/kg body wt/d) in a volume of 100 ml water via gavage
from 3 h after the last injection of MPTP. The neurotoxic effect
of MPTP depends on several key toxicokinetic steps such as its
conversion into MPP
+ in glial cells by MAO-B and the uptake of
MPP
+ by dopaminergic neurons. Przedborski and colleagues [20]
have shown that sufficient amount of MPTP is converted into
MPP
+ within 90 min of the last injection of MPTP in an acute
MPTP model. Therefore, to avoid any possible influence of
NaPB on entry and conversion of MPTP into MPP
+ in the
midbrain, oral treatment began 3 h after the last injection of
MPTP. On the other hand, for long-term treatment, mice with
chronic MPTP intoxication received a lower dose of NaPB
(100 mg/kg body wt/d) via gavage from the 3
rd injection of
MPTP/probenecid. Control MPTP mice received only 100 ml
water via gavage everyday.
On the other hand, FTI and GGTI were solubilized in normal
saline and mice were treated with FTI and GGTI daily via
intraperitoneal (i.p.) injection at doses of 5 or 10 mg/kg body wt/d
starting from 3 h after the last injection of MPTP.
Activation of p21
ras and p21
rac
Activation of p21
ras was monitored as described before [17,21].
Briefly, after 6 h of MPTP insult, ventral midbrain was dissected
out and frozen immediately on dry ice. The p21
ras-binding
domain (RBD) of the p21
ras effector kinase Raf1 has been shown
to bind specifically to the GTP-bound (active) form of p21
ras
proteins. Therefore, using an assay kit from Upstate Biotechnology
(Waltham, MA), ventral midbrain tissues were homogenized with
lysis buffer containing inhibitors of different proteases and kinases
followed by immuno-pull down of active p21
ras using Raf-RBD-
GST beads. Then the amount of activated p21
ras was determined
in GST beads by a Western blot using a p21
ras specific antibody.
As activated p21
ras interacts with Raf1, activated p21
rac
interacts with p21-activated kinase (PAK). Accordingly, p21
rac-
interacting domain (RID) of PAK binds specifically to the GTP-
bound (active) form of p21
rac. Therefore, using an assay kit from
Upstate Biotechnology (Waltham, MA), PAK-RID-GST beads
were used to immuno-pull down active p21
rac from cell lysates
followed by a Western blot using a p21
rac specific antibody.
Semi-quantitative RT-PCR Analysis for Proinflammatory
Molecules (iNOS, IL-1b and TNF-a) and Glial Cell Markers
Total RNA was isolated from ventral midbrain using Ultraspec-
II RNA reagent (Biotecx Laboratories, Inc., Houston, TX)
following manufacturer’s protocol. To remove any contaminating
genomic DNA, total RNA was digested with DNase. RT-PCR was
carried out as described earlier [9,15,17] using a RT-PCR kit
(Clontech, Mountain View, CA) and following primers.
iNOS: Sense: 59-CCCTTCCGAAGTTTCTGGCAGCAGC-
39.
Antisense: 59-GGCTGTCAGAGCCTCGTGGCTTTGG-39.
IL-1b: Sense: 59-CTCCATGAGCTTTGTACAAGG-39.
Antisense: 59-TGCTGATGTACCAGTTGGGG-39.
TNF-a: Sense: 59-TTCTGTCTACTGAACTTCGGGGT-
GATCGGTCC-39.
Antisense: 59-GTATGAGATAGCAAATCGGCT-
GACGGTGTGGG-39.
CD11b: Sense: 59-GTGAGGATTCCTACGGGACC-
CAGGT-39.
Antisense: 59-GGCGTACTTCACAGGCAGCTCCAAC-39.
GFAP: Sense: 59- GGCGCTCAATGCTGGCTTCA-39.
Antisense: 59- TCTGCCTCCAGCCTCAGGTT-39.
GAPDH: Sense: 59-GGTGAAGGTCGGTGTGAACG-39.
Antisense: 59-TTGGCTCCACCCTTCAAGTG-39.
Real-time PCR Analysis
It was performed in the ABI-Prism7700 sequence detection
system (Applied Biosystems, Foster City, CA) as described earlier
[9,15,17] using TaqMan Universal Master mix and optimized
concentrations of FAM-labeled probes and primers. Data were
processed by the ABI Sequence Detection System 1.6 software.
Immunohistochemistry and Quantitative Morphology
Seven days after MPTP intoxication, mice were sacrificed and
their brains fixed, embedded, and processed for tyrosine hydrox-
ylase (TH) staining as previously described [9,17,22]. Total
numbers of TH-positive neurons in SNpc were counted stereo-
logically with STEREO INVESTIGATOR software (Micro-
Brightfield, Williston, VT) by using an optical fractionator.
Quantitation of striatal TH immunostaining was performed as
described [9,17,22]. Optical density measurements were obtained
by digital image analysis (Scion, Frederick, MD). Striatal TH
optical density reflected dopaminergic fiber innervation. For
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mouse CD11b (1:100), goat anti-mouse GFAP (1:100), rabbit anti
NF-kB p65 (1:100), goat anti-NF-kB p65 (1:100), rabbit anti NF-
kB p50 (1:100), and rabbit anti-mouse iNOS (1:250) were used.
The samples were mounted and observed under a Bio-Rad
MRC1024ES confocal laser scanning microscope.
HPLC Analysis of Striatal Dopamine and its Metabolite
Levels
Striatal level of dopamine, DOPAC (3, 4-dihydroxyphenylacetic
acid) and HVA (homovanillic acid) was quantified as described
earlier [9,17,19]. Briefly, mice were sacrificed by cervical
dislocation after 7 days of MPTP intoxication and their striata
were collected and immediately frozen in dry ice and stored at
280uC until analysis. On the day of the analysis, tissues were
sonicated in 0.2 M perchloric acid containing isoproterenol and
resulting homogenates were centrifuged at 20,000 6g for 15 min
at 4C. After pH adjustment and filtration, 10 ml of supernatant
was injected onto an Eicompak SC-3ODS column (Complete
Stand-Alone HPLC-ECD System EiCOMHTEC-500 from JM
Science Inc., Grand Island, NY) and analyzed following manu-
facturer’s protocol.
Analysis of GSH
Nigral tissues were dissected and then sonicated in 0.2 M
perchloric acid solution followed by centrifugation of nigral
extracts at 12,000 rpm for 10 mins at 4uC. Resulting supernatants
were analyzed for GSH in Complete Stand-Alone HPLC-ECD
System EiCOMHTEC-500 using gold working electrode (Eicom
We-AU) and mobile phase containing 99% 0.1 M sodium
phosphate buffer (pH 2.5), 1% MeOH (v/v), and 50 mg/L
EDTA-2Na.
Behavioral Analyses
Two types of behavioral experiments were conducted. This
included open field experiment for locomotor activity and rotorod
experiment for feet movement as described earlier [9,17,19].
Locomotor activity was measured after 7 d of the last dose of
MPTP injection in Digiscan Monitor (Omnitech Electronics, Inc.,
Columbus, OH). This Digiscan Monitor records stereotypy and
rearing, behaviors that are directly controlled by striatum, as well
as other basic locomotion parameters, such as horizontal activity,
total distance traveled, number of movements, movement time,
rest time, mean distance, mean time, center time etc. Before any
insult or treatment, mice were placed inside the Digiscan Infra-red
Activity Monitor for 10 min daily and on rotorod for 10 min daily
for 3 consecutive days to train them and record their baseline
values. Briefly, animals were removed directly from their cages
and gently placed nose first into a specified corner of the open-field
apparatus and after release, data acquisition began at every 5 min
interval. DIGISCAN software was used to analyze and store
horizontal and vertical activity data, which were monitored
automatically by infra-red beams. In rotorod, the feet movement
of the mice was observed at different speeds. To eliminate stress
and fatigues, mice were given a 5-min rest interval. Then 7 d after
the last dose of MPTP, open field and rotorod tests were carried
out twice at 6 h interval on each mouse separately [9,17].
Locomotor activity measures were assessed after baseline value
comparison.
Statistics
All values are expressed as means 6 SEM. Differences among
means were analyzed by one- or two-way ANOVA considering
time, dose or treatment as the independent factor. The one way
ANOVA was performed while analyzing dose-dependent effect of
NaPB on the induction of NO production or the activation of NF-
kB in activated microglial cells. On the other hand, two-way
ANOVA was employed to analyze the effect of Dp21
rac or Dp21
ras
on LPS-induced time-dependent production of superoxide. In
other cases, Student’s t-test was used to compare outcome between
two groups (e.g. control vs MPTP, MPTP vs NaPB etc).
Results
NaPB Attenuates the Expression of iNOS and
Proinflammatory Cytokines in Activated Mouse Microglia
and Human Astroglia
Activated microglia and astroglia are known to produce
excessive amount of NO having the potential of damaging
neurons in neurodegenerative disorders. We investigated the
effect of NaPB on the expression of iNOS in microglia. LPS is a
prototype inducer of various proinflammatory molecules in
different cell types including mouse microglia. Therefore,
primary mouse microglia preincubated with different doses of
NaPB for 6 h were stimulated with LPS under serum-free
condition. Although at lower concentration (100 mM), NaPB was
not effective in inhibiting the production of NO, at higher
concentrations (.200 mM), NaPB markedly suppressed LPS-
induced production of NO in microglia (Figure 1A). However, 1
or 2 h preincubation of microglia with NaPB was not sufficient
to exhibit NO inhibition (data not shown). Because NaPB is a
known inhibitor of histone deacetylase (HDAC), we investigated
if other inhibitors of HDAC also shared this property. We used
trichostatin A (TSA) and sodium butyrate (NaBu) for this
purpose. Although similar to NaPB, TSA attenuated LPS-
induced production of NO, NaBu stimulated the production of
NO in LPS-stimulated microglial cells (Figure 1D) suggesting that
all HDAC inhibitors do not have anti-inflammatory property. To
understand the mechanism for NaPB-mediated suppression of
NO production, we investigated the effect of NaPB on protein
and mRNA expression of iNOS in microglia. As evident from
Western blot (Figure 1B) and RT-PCR (Figure 1C), NaPB dose-
dependently inhibited LPS-induced protein and mRNA expres-
sion of iNOS in microglia. (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) results show that NaPB
was not toxic to microglia at any of the concentrations tested
(data not shown) suggesting that the inhibitory effect of NaPB on
microglial expression of iNOS was not due to any change in cell
viability. In addition to producing NO, activated microglia also
secrete a broad range of proinflammatory molecules. Therefore,
we examined if NaPB was capable of suppressing the expression
of proinflammatory cytokines in primary mouse microglia.
Similar to the inhibition of iNOS, NaPB dose-dependently
inhibited the production of TNF-a and IL-1b protein in
activated microglia (Table-1).
Next, we examined if NaPB could suppress the expression of
iNOS in human brain cells. Astroglia are the major glial cells in
the CNS and astroglial activation also plays a role in various
neurodegenerative disorders. Earlier we have found that IL-1b is
the only cytokine that induces iNOS in primary human astroglia
[23]. Consistently, IL-1b induced the production of nitrite
(Figure 1E) and the activation of human iNOS promoter
(Figure 1F) in primary astroglia isolated from human fetal brains.
Interestingly, NaPB markedly inhibited IL-1b-induced production
of NO (Figure 1E) and the activation of iNOS promoter (Figure 1F)
in human astroglia.
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PLoS ONE | www.plosone.org 4 June 2012 | Volume 7 | Issue 6 | e38113NaPB Inhibits Microglial Activation of NF-kB
LPS and other inflammatory stimuli including MPP
+ are known
to induce iNOS expression via activation of NF-kB [8,9,24,25].
Because NaPB attenuated the expression of iNOS in glial cells, we
examined the effect of NaPB on the activation of NF-kB.
Activation of NF-kB was monitored by IkBa phosphorylation,
DNA binding activity by EMSA and transcriptional activity by
reporter assays. As expected, treatment of BV-2 microglial cells
Figure 1. Dose-dependent inhibition of NO production by NaPB in mouse and human glial cells. Primary mouse microglia were treated
with different concentrations of NaPB for 6 h followed by stimulation with LPS under serum-free condition. After 24 h of stimulation, concentrations
of nitrite were measured in supernatants (A) and the level of iNOS protein was monitored in cells by Western blot (B). Results are mean + SD of three
different experiments.
ap,0.001 vs control;
bp,0.05 vs LPS;
cp,0.001 vs LPS. After 5 h of stimulation, the expression of iNOS mRNA was monitored by
semi-quantitative RT-PCR (C). Cells preincubated with different concentration of trichostatin A (TSA) and sodium butyrate (NaBu) for 6 h were
stimulated with LPS for 24 h under serum-free condition followed by monitoring the level of nitrite in supernatants (D). Results are mean + S.D. of
three different experiments.
ap,0.001 vs control;
bp,0.05 vs LPS;
c,dp,0.001 vs LPS. Primary human astroglia isolated from fetal brain tissues were
treated with different concentrations of NaPB for 6 h followed by stimulation with IL-1b under serum-free condition. After 48 h of stimulation,
concentrations of nitrite (E) were measured in supernatants. Human astroglia plated at 70–80% confluence in 12-well plates were cotransfected with
0.25 mg of phiNOS(7.2)Luc and 12.5 ng of pRL-TK using the Lipofectamine-Plus (Invitrogen). Twenty-four h after transfection, cells received NaPB.
After 6 h of incubation, cells were stimulated with IL-1b (20 ng/ml) for 12 h. Firefly (ff-Luc) and Renilla (r-Luc) luciferase activities were obtained by
analyzing the total cell extract (F). Data are mean + S.D. of three different experiments.
ap,0.001 versus control;
bp,0.05 versus IL-1b;
cp,0.001
versus IL-1b.
doi:10.1371/journal.pone.0038113.g001
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(Figure 2A). However, NaPB inhibited LPS-induced phosphory-
lation of IkBa suggesting that NaPB functions upstream of IkBa
phosphorylation. Accordingly, LPS induced the DNA-binding
activity of NF-kB in microglial cells, which was inhibited by NaPB
(Figure 2B). We then tested the effect of NaPB on the
transcriptional activity of NF-kB. As expected, LPS induced NF-
kB-dependent transcription of luciferase (Figure 2C). Consistent to
the effect of NaPB on the phosphorylation of IkBa and the DNA
binding activity of NF-kB, NaPB also suppressed the transcrip-
tional activity of NF-kB in a dose-dependent manner in LPS-
stimulated microglia (Figure 2C).
Mouse iNOS promoter harbors two NF-kB binding sites – distal
(nucleotides 2971 to 2962) and proximal (nucleotides 285 to
276) [26]. At first, we employed chromatin immunoprecipitation
(ChIP) assay to study the recruitment of RelA p65 to each of these
two NF-kB binding sites. After immunoprecipitation of LPS-
stimulated microglial chromatin fragments by antibodies against
p65, we were able to amplify 307 bp fragments flanking the
proximal NF-kB element (Figure 2D). However, after several
attempts, we failed to detect any amplification product spanning
the distal NF-kB binding site (data not shown). These results
suggest that LPS induced the recruitment of p65 to the proximal
NF-kB-binding site of the mouse iNOS promoter in microglia.
Therefore, next we examined the effect of NaPB on the
recruitment of p65 to the proximal NF-kB binding site of the
iNOS promoter. Consistent to the inhibition of iNOS mRNA
expression, NaPB inhibited the recruitment of p65 to the iNOS
promoter in LPS-stimulated microglia (Figure 2D). On the other
hand, no amplification product was observed in any of the
immunoprecipitates obtained with control IgG (left four lanes of
Figure 2D), suggesting the specificity of these interactions. These
results also suggest that NaPB interferes with the recruitment of
NF-kB to the iNOS promoter.
Intermediates of the Mevalonate Pathway Reverse the
Inhibitory Effect of NaPB on Microglial NF-kB Activation
The requirement of at least 6 h of preincubation of cells with
NaPB to see its anti-inflammatory effect suggests that metabolite(s)
sensitive to NaPB may be involved in the process. Earlier
Brahmachari and Pahan [15] have demonstrated that intermedi-
ates of the mevalonate pathway play a role in the expression of
iNOS and proinflammatory cytokines in glial cells. End product of
the mevalonate pathway is cholesterol and therefore, we investi-
gated if NaPB had any effect on the level of cholesterol in vivo in
mice. Interestingly, after 7 d of oral feeding at a dose of 200 mg/
kg body wt/d, NaPB reduced the level of cholesterol in serum of
mice by about 30%; and this reduction was comparable to that
(,29%) by the so-called cholesterol-lowering drug pravastatin
(Figure S1). These results are important as it suggests that NaPB
may be used to lower cholesterol in patients with hypercholester-
olemia.
Next, we examined the role of different members of the
mevalonate pathway in NF-kB inhibitory effect of NaPB.
Interestingly, HMG-CoA, mevalonate, geranylgeranyl pyrophos-
phate (GGPP), and farnesyl pyrophosphate (FPP) abrogated the
inhibitory effect of NaPB on the activation of NF-kB (Figure 2E) in
microglial cells. On the other hand, cholesterol and coenzyme Q
(end products of the mevalonate pathway) had no effect on NaPB-
mediated inhibition of NF-kB activation (Figure 2E). These results
suggest that depletion of intermediary products rather than end
products of the mevalonate pathway is responsible for the
observed anti-inflammatory effect of NaPB.
NaPB Inhibits MPP
+-induced Expression of Microglial
Proinflammatory Molecules
Glial inflammation is a critical component of PD pathogenesis
[2,9,27,28] which is mirrored in MPTP mouse models. The
neurotoxic effect of MPTP depends on its conversion into MPP
+.
In glial cells, MAO-B converts MPTP to MPP
+, which then leads
to glial activation [1]. MPP
+ is able to stimulate the microglial
expression of inflammatory molecules including NO, TNF-a, IL-
1b, and IL-6 as reported by us [9,15,17,29] and different other
groups [30,31]. Although, a well characterized receptor for MPP
+
was not known in microglial cells until recent past, a new study
[32] has reported that low dose of MPP
+ stimulates microglial
activation via the engagement of cysteinyl leukotriene receptor
(CysLT1R). According to their study, MPP
+- dependent activation
of CysLT1R and its subsequent translocation from plasma
membrane to cytosol plays a critical role in the process of
microglial activation. Therefore, we investigated if MPP
+ could
induce the expression of proinflammatory molecules in microglia
and if NaPB suppressed such induction. RT-PCR (Figure S2A),
western blot (Figure S2B) and real-time PCR (Figure S2C) analysis
showed that MPP
+ alone induced the expression of iNOS mRNA
and protein and that NaPB suppressed MPP
+-induced iNOS
mRNA and protein expression (Figure S2A–C) in microglial cells.
Similarly, MPP
+ also markedly induced the mRNA expression of
IL-1b and TNF-a in microglial cells (Figure S2A, S2D & S2E).
However, NaPB inhibited MPP
+-induced expression of TNF-a
and IL-1b mRNAs in a dose-dependent manner (Figure S2A, S2D
& S2E) suggesting that NaPB is capable of inhibiting MPP
+-
induced expression of microglial proinflammatory molecules.
NaPB Inhibits the Production of Reactive Oxygen Species
(ROS) from Activated Microglia
Oxidative stress plays an important role in the pathogenesis of
various neurodegenerative diseases including PD. We examined if
Parkinsonian toxin MPP
+ induced the production of ROS from
Table 1. Attenuation of proinflammatory cytokine production by NaPB in primary mouse microglia.
Cytokine (ng/mg
protein/24 h) Treatment
Control LPS LPS+NaPB (0.1 mM) LPS+NaPB (0.2 mM) LPS+NaPB (0.5 mM) NaPB (0.5 mM) only
TNF-a 01 8 . 4 +3.1 16.8+1.5 12.7+0.8 8.6+1.1
a 0
IL-1b 01 1 . 2 +2.9 9.9+1.4 7.5+1.1 5.3+0.6
a 0
Primary microglia preincubated with different concentrations of NaPB for 6 h were stimulated with LPS for 24 h followed by quantification of TNF-a and IL-1b in
supernatants by ELISA. Results are mean + SD of three independent experiments.
ap,0.001 vs LPS.
doi:10.1371/journal.pone.0038113.t001
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PLoS ONE | www.plosone.org 6 June 2012 | Volume 7 | Issue 6 | e38113Figure 2. NaPB attenuates activation of NF-kB in mouse microglial cells. (A) BV-2 microglial cells preincubated with 0.5 mM NaPB for 6 h
were stimulated with 1 mg/ml LPS. At different minute of stimulation, the level of phospho-IkBa was monitored by Western blot. B) Cells
preincubated with different concentrations of NaPB for 6 h were stimulated with LPS for 1 h followed by monitoring the DNA-binding activity of NF-
kB by EMSA. (C) Cells plated in 12-well plates were co-transfected with 0.25 mg of PBIIX-Luc (an NF-kB-dependent reporter construct) and 12.5 ng of
pRL-TK. Twenty-four h after transfection, cells received different concentrations of NaPB. After 6 h of incubation, cells were stimulated with LPS for
4 h. Firefly (ff-Luc) and Renilla (r-Luc) luciferase activities were obtained by analyzing the total cell extract. Results are mean + S.D. of three different
experiments.
ap,0.001 vs control;
bp,0.05 vs LPS;
cp,0.001 vs LPS. D) Cells preincubated with 0.5 mM NaPB for 6 h were stimulated with LPS for 2 h
followed by monitoring the recruitment of RelA p65 to the mouse iNOS promoter by ChIP assay. E) Cells were co-transfected with 0.25 mg of PBIIX-
Luc and 12.5 ng of pRL-TK. Twenty-four hours after transfection, cells were incubated with NaPB in the presence or absence of HMG-CoA,
mevalonate, FPP, GGPP, cholesterol, and coenzyme Q. After 6 h of incubation, cells were stimulated with LPS for 4 h followed by assay of firefly (ff-
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PLoS ONE | www.plosone.org 7 June 2012 | Volume 7 | Issue 6 | e38113microglia and if NaPB could attenuate such ROS production. To
monitor the generation of intracellular ROS in BV-2 microglial
cells, we used a cell-permeant fluorescent probe. As seen in
figure 3A, MPP
+ markedly induced the generation of ROS within
15 min of stimulation. However, NaPB strongly inhibited MPP
+-
induced production of intracellular ROS (Figure 3A). Recent
studies identify NADPH oxidase as the most important ROS
(superoxide radicals)-producing molecule in response to different
inflammatory stimuli [3,4,33,34]. Accordingly, MPP
+ also induced
the production of superoxide from microglial cells in a time-
dependent manner (Figure 3B). The production of superoxide was
observed as early as 5 min of stimulation, which peaked at 10 min
(Figure 3B). Consistent to the inhibition of endogenous ROS
(Figure 3A), NaPB attenuated MPP
+-induced production of
superoxide (Figure 3B). Because various stimuli and neurotoxins
are capable of producing ROS, we examined if NaPB could
suppress the production of ROS in response to different
inflammatory stimuli. As expected, LPS, TNF-a, IL-1b, HIV-1
gp120, and fibrillar Ab1-42 peptides induced the production of
superoxide in microglial cells (Figure 3C). However, NaPB
knocked down LPS-, TNF-a-, IL-1b-, gp120-, and Ab-induced
production of superoxide in microglia (Figure 3C). These results
suggest that NaPB could be used as an antioxidant.
Because NaPB exhibited anti-inflammatory activity via modu-
lation of mevalonate metabolites (Figure 2E), we investigated if
mevalonate metabolites could reverse the antioxidant effect of
NaPB. Interestingly, HMG-CoA, mevalonate and GGPP, but not
FPP, abolished the inhibitory effect of NaPB on the production of
superoxide in microglial cells (Figure 3D). On the other hand,
cholesterol and coenzyme Q had no effect on NaPB-mediated
inhibition of superoxide production (Figure 3D). These results
suggest that depletion of intermediary products rather than end
products of the mevalonate pathway is also responsible for the
antioxidant effect of NaPB. Furthermore, due to that geranylger-
anylation is required for the activation of p21
rac and that
farnesylation is needed for the activation of p21
ras, these results
suggest that p21
rac, but not p21
ras, may be involved in ROS
generation.
NaPB Mediates its Anti-inflammatory and Antioxidant
Effects through Inhibition of p21
ras and p21
rac Activation
Reversal of anti-inflammatory and antioxidant effects of NaPB
by intermediates, but not end products, of the mevalonate
pathway, suggest a possible involvement of farnesylation and/or
geranylgeranylation reactions in inflammation and oxidative
stress. Because farnesylation and geranylgeranylation are required
for activation of p21
ras and p21
rac, respectively, we examined the
effect of farnesyltransferase inhibitor (FTI) and geranylgeranyl-
transferase inhibitor (GGTI) on NF-kB activation and superoxide
production in microglial cells. Inhibition of LPS-induced activa-
tion of NF-kB by both FTI and GGTI (Figure 4A) suggests that
both p21
ras and p21
rac could be involved in microglial activation of
NF-kB. To confirm the involvement of p21
ras and p21
rac,w e
examined the effect of dominant-negative mutants of p21
ras
(Dp21
ras) and p21
rac (Dp21
rac) on LPS-induced activation of NF-
kB and expression of iNOS. LPS induced the transcriptional
activity of NF-kB (Figure 5A) and the expression of iNOS mRNA
(Figure 5B) in empty vector-transfected microglial cells. However,
both Dp21
ras and Dp21
rac suppressed LPS-induced activation of
NF-kB (Figure 5A) and expression of iNOS (Figure 5B). This was
further corroborated by siRNA knockdown of p21
ras. Ras siRNA
decreased the protein expression of p21
ras (Figure 5C) and
inhibited LPS-induced expression of iNOS mRNA (Figure 5D)
and production of nitrite (Figure 5E). Accordingly, RasV12, a
constitutively-active mutant of p21
ras, alone induced the activation
of NF-kB (Figure 5F) and the expression of iNOS mRNA
(Figure 5G) suggesting that activation of p21
ras alone is sufficient
for the activation of NF-kB and the expression of iNOS. NaPB, in
this instance as well, attenuated RasV12-induced activation of NF-
kB and expression of iNOS (Figure 5F–G).
Although both FTI and GGTI inhibited the activation of NF-
kB, only GGTI, but not FTI, inhibited the production of
superoxide from LPS-stimulated microglial cells (Figure 4B)
suggesting that p21
rac, but not p21
ras, could be involved in the
generation of superoxide. To further confirm this finding, we
examined the effect of dominant-negative mutants of p21
ras
(Dp21
ras) and p21
rac (Dp21
rac) on LPS-induced production of
superoxide. Consistently, Dp21
rac, but not Dp21
ras, knocked down
LPS-induced production of superoxide in microglial cells. This was
not seen in empty vector (pcDNA3) controls (Figure 4C). Next, we
examined the effect of NaPB on the activation of p21
ras and
p21
rac. Marked activation of p21
ras and p21
rac was observed
within minutes of LPS stimulation (Figure 4D). However, NaPB
markedly suppressed LPS-induced activation of both p21
ras and
p21
rac in microglial cells (Figure 4D). These results suggest that
NaPB attenuates the expression of proinflammatory molecules and
the production of ROS in microglia probably by suppressing the
activation of p21
ras and p21
rac.
Oral Administration of NaPB Attenuates the Activation of
p21
ras and p21
rac in vivo in the Nigra of MPTP-intoxicated
Mice
Because NaPB inhibits the activation of p21
ras and p21
rac in
microglia, we examined if NaPB was capable of suppressing the
activation of these small G proteins in vivo in the nigra of MPTP-
insulted mice, an animal model of PD. It is clearly evident from
figure 6A & 6B that MPTP intoxication markedly induced the
activation of p21
ras and p21
rac in the nigra compared to saline
treatment. However, mice that were treated with NaPB (200 mg/
kg body wt/day) through gavage from 1 d prior to the MPTP
intoxication exhibited much decreased activation of both p21
ras
and p21
rac (Figure 6A & 6B) suggesting that oral NaPB is capable
of inhibiting the activation of p21
ras and p21
rac in vivo in the nigra.
NaPB Inhibits the Activation of NF-kB in vivo in the Nigra
of MPTP-intoxicated Mice
Because NaPB inhibited the activation of NF-kB in glial cells
(Figure 2), we examined if NaPB was capable of suppressing the
activation of NF-kB in vivo in the nigra of MPTP-intoxicated mice.
It is clearly evident from figure 6C and 6D that MPTP
intoxication markedly induced the expression of RelA p65 in the
SNpc as compared to saline treatment. Double-label immunoflu-
orescence analysis indicates that p65 was principally expressed in
CD11b-positive microglia andGFAP-positive astroglia (Figure6C).
Next, mice were treated with NaPB (200 mg/kg body wt/day) via
gavage from 3 h after the last injection of MPTP and the
activation of NF-kB was examined 24 h after the last injection of
MPTP. As evident from figure 6C, NaPB markedly inhibited the
level of p65 in vivo in the SNpc of MPTP-intoxicated mice.
Luc) and Renilla (r-Luc) luciferase activities. Results are mean + S.D. of three different experiments.
ap,0.001 vs control;
bp,0.001 vs LPS;
cp,0.001 vs
LPS+NaPB.
doi:10.1371/journal.pone.0038113.g002
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Molecules in vivo in the Nigra of MPTP-intoxicated Mice
Inflammation plays a role in the loss of dopaminergic neurons in
PD and its animal model [9,17,35,36]. Because NaPB inhibited
the expression of proinflammatory molecules in glial cells and
suppressed the activation of small G proteins (p21
ras and p21
rac)
and NF-kB in vivo in the nigra of MPTP-intoxicated mice, we
examined if NaPB was able to suppress the expression of iNOS in
vivo in the SNpc of MPTP-insulted mice. Immunofluorescence
analysis for iNOS in ventral midbrain sections shows that MPTP
intoxication led to marked increase in nigral iNOS protein
expression and that iNOS co-localized with GFAP-positive
astroglia and CD11b-positive microglia (Figure 7A). However,
oral administration of NaPB suppressed MPTP-induced expres-
sion of iNOS protein (Figure 7A–B). As shown by semi-
quantitative RT-PCR (Figure 7C) and quantitative real-time
Figure 3. NaPB inhibits the production of ROS in mouse microglial cells. Cells were treated with 500 mM NaPB for 6 h followed by
stimulation with 1 mM MPP
+. At 15 min of stimulation, the generation of ROS was monitored by carboxy-H2DCFDA (A). At different intervals
(measured in minutes), superoxide production was assayed in whole cells (B). Cells preincubated with 500 mM NaPB for 6 h were stimulated with LPS
(1 mg/ml), TNF-a (50 ng/ml), IL-1b (20 ng/ml), gp120 (200 pg/ml), and fibrillar Ab1-42 (1 mM). At 10 min of stimulation, superoxide production was
assayed in whole cells (C). Results are mean + SD of three different experiments.
ap,0.001 vs control;
bp,0.001 vs stimuli. D) Cells were incubated
with NaPB in the presence or absence of HMG-CoA, mevalonate, GGPP, FPP, cholesterol, and coenzyme Q. After 6 h of incubation, cells were
stimulated with LPS for 10 min followed by assay of superoxide. Results are mean + SD of three different experiments.
ap,0.001 vs control;
bp,0.001
vs LPS;
cp,0.001 vs LPS+NaPB.
doi:10.1371/journal.pone.0038113.g003
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increase in mRNA expression of iNOS, IL-1b and TNF-a in the
nigra. However, NaPB strongly inhibited MPTP-induced expres-
sion of these proinflammatory molecules in vivo in the nigra
(Figure 7C–D). These results suggest NaPB can inhibit the
expression of proinflammatory molecules in vivo in the SNpc of
MPTP-intoxicated mice.
Are the Activation of p21
ras and the Expression of iNOS in
the Nigra of MPTP-intoxicated Mice Dependent on the
Loss of Dopaminergic Neurons?
Although Przedborski and colleagues [37] have shown that
microglial activation occurs much earlier to neuronal death in
MPTP mouse model, according to Gao et al [38], activation of
glia, specifically microglia, is secondary to neurodegeneration.
Therefore, in order to delineate whether glial activation-associated
events happen before or after the loss of dopaminergic neurons, we
performed a time-course study to monitor nigral activation of
p21
ras and expression of iNOS and striatal loss of dopamine in
MPTP-intoxicated mice. Micropunches from the nigra were used
for monitoring p21
ras and iNOS. The activation of p21
ras began as
early as 3 h after the last injection of MPTP, peaked at 6 h and
decreased afterwards until the duration (24 h) of the study (Figure
S3A). On the other hand, the expression of iNOS mRNA as
revealed by RT-PCR (Figure S3B) and real-time PCR (Figure
S3C) was visible as early as 6 h and maximum at 12 h. As
expected from results above, NaPB treatment markedly inhibited
the activation of p21
ras and the expression of iNOS mRNA in vivo
the nigra at all time points tested (Figure S3A–C). In contrast to
the activation of p21
ras and the expression of iNOS, we did not
notice any loss of striatal dopamine within 24 h of MPTP
intoxication (Figure S3D). Significant loss of dopamine was
observed on day 5 and it was maximum on day 7 (Figure S3D).
These results suggest that glial inflammation/activation appears
before neuronal loss in MPTP mouse model of PD.
NaPB Inhibits the Activation of Glial Cells in vivo in the
Nigra of MPTP-intoxicated Mice
Recently activation of glial cells is being considered as a
pathological hallmark in PD and other neurodegenerative
disorders. Increased expression of CD11b, the beta-integrin
marker of microglia, represents microglial activation during
neurodegenerative inflammation (18). Similarly, upon activation,
astrocytes also express enhanced level of GFAP, which is
considered as a marker protein for astrogliosis [9,39]. We
investigated if NaPB could attenuate MPTP-induced activation
Figure 4. NaPB inhibits the activation of NF-kB and the production of ROS via modulation of p21
ras and p21
rac. A) Mouse BV-2
microglial cells preincubated with different concentrations of FTI and GGTI were stimulated with LPS for 60 min followed by monitoring the
activation of NF-kB by EMSA. B) Cells preincubated with different concentrations of FTI and GGTI were stimulated with LPS for 10 min followed by
monitoring the production of superoxide. Results are mean + SD of three different experiments.
ap,0.001 vs control;
bp,0.001 vs LPS. C) Cells were
transfected with Dp21
ras, Dp21
rac or an empty vector using Lipofectamine Plus. Twenty-four hour after transfection, cells were stimulated with LPS
followed by monitoring superoxide production at 15 and 30 min of stimulation.
ap,0.001 vs control;
bp,0.001 vs LPS-15 min;
cp,0.001 vs LPS-
30 min. D) Cells preincubated with 500 mM NaPB were stimulated with LPS. At different time points, activation of p21
ras and p21
rac was monitored.
Results represent three independent experiments.
doi:10.1371/journal.pone.0038113.g004
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immunofluorescence analyses of CD11b and GFAP in ventral
midbrain sections (Figure S4A), MPTP intoxication led to marked
increase in nigral CD11b and GFAP protein expression. However,
oral treatment of MPTP-intoxicated mice with NaPB led to the
inhibition of GFAP and CD11b protein expression (Figure S4A). It
is clearly evident from semi-quantitative RT-PCR in Figure S4B
and real-time PCR in Figure S4C that MPTP intoxication led to
marked increase in mRNA expression of both CD11b and GFAP
in the nigra. However, similar to the inhibition of proinflamma-
tory molecules, NaPB suppressed MPTP-induced expression of
CD11b and GFAP in vivo in the nigra (Figure S4B–C). These
results suggest that NaPB is capable of attenuating glial activation
in vivo in the nigra of MPTP-intoxicated mice.
NaPB Protects Against MPTP-induced
Neurodegeneration
MPTP-intoxication led to approximately 75% loss of SNpc TH-
positive neurons (Figure 8A & C) and 70% reduction of striatal
TH ODs (Figure 8B & D) compared with saline-injected controls.
However, in MPTP-injected mice treated with NaPB, less
reduction in SNpc TH-positive neurons and striatal TH ODs
was observed (Figure 8A–D). Next to determine whether NaPB
protects against biochemical deficits caused by MPTP, we
quantified levels of dopamine (DA) and two of its metabolites,
dihydroxyphenylacetic acid (DOPAC) and homovanillic acid
(HVA), in the striata 7 days after the MPTP treatment. As
evident from figure 8E, MPTP intoxication led to about 76%
decrease in striatal DA compared to striata of saline-injected mice.
Figure 5. Role of p21
ras and p21
rac in the induction of iNOS and the activation of NF-kB in microglial cells. A) Cells plated in 12-well
plates were co-transfected with 0.2 mg PBIIX-Luc and 0.2 mg Dp21
ras, Dp21
rac or an empty vector. Each transfection also included 12.5 ng of pRL-TK.
Twenty-four hour after transfection, cells were stimulated with LPS for 4 h. Firefly (ff-Luc) and Renilla (r-Luc) luciferase activities were obtained by
analyzing the total cell extract. Results are mean + S.D. of three different experiments.
ap,0.001 vs control;
bp,0.001 vs LPS. B) Cells were transfected
with Dp21
ras, Dp21
rac or an empty vector. Twenty-four hour after transfection, cells were stimulated with LPS for 5 h under serum-free condition
followed by monitoring the expression of iNOS mRNA by RT-PCR. Cells were transfected with either control siRNA or Ras siRNA and 24 h after
transfection, cells were stimulated with LPS for 5 h followed by monitoring the expression of Ras protein by Western blot (C) and iNOS mRNA by RT-
PCR (D). After transfection, cells were stimulated with LPS for 24 h followed by monitoring the level of nitrite in supernatants (E).
ap,0.001 vs control;
bp,0.001 vs LPS. F) Cells plated in 12-well plates were co-transfected with 0.2 mg PBIIX-Luc and different amounts of either RasV12 (a constitutively-
active mutant of p21
ras) or control vector. Each transfection also included 12.5 ng of pRL-TK. Twenty-four hour after transfection, cells were treated
with NaPB for 6 h under serum-free condition followed by monitoring firefly (ff-Luc) and Renilla (r-Luc) luciferase activities in total cell extract.G )
Under similar condition, the effect of RasV12 and an empty vector on the expression of iNOS mRNA was monitored in cells. Results are mean + S.D. of
three different experiments.
ap,0.001 vs empty vector (0.2 mg);
bp,0.001 vs RasV12 (0.1 mg);
cp,0.001 vs RasV12 (0.2 mg).
doi:10.1371/journal.pone.0038113.g005
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showed only 20–25% decrease in striatal dopamine (Figure 8E).
Because NaPB inhibited the activation of p21
rac and the
production of ROS from microglial cells and attenuated the
activation of p21
rac in vivo in the nigra of MPTP-insulted mice, we
examined the effect of NaPB on nigral redox state in MPTP-
insulted mice. Reduced glutathione (GSH) is the master anti-
oxidant, which protects all cells including dopaminergic neurons
from oxidative attack. We monitored the level of nigral GSH by
HPLC. As expected, MPTP intoxication led to approximately
72% loss of GSH (Figure 8F). However, after NaPB treatment,
MPTP-intoxicated mice showed only 18% loss of nigral GSH
(Figure 8F) suggesting that NaPB is capable of improving the
nigral redox state in MPTP-intoxicated mice.
NaPB Improves Locomotor Functions in MPTP-
intoxicated Mice
The ultimate therapeutic goal of neuroprotection is to decrease
functional impairment. Therefore, to examine whether NaPB
protects not only against structural and neurotransmitter damage
but also against functional deficits caused by MPTP, we monitored
locomotor and open-field activities. As reported earlier [17,19,29],
MPTP injection caused marked decrease in rotorod performance
(Figure S5A), movement time (Figure S 5B), total distance (Figure
S5C), stereotypy (Figure S5E), rearing (Figure S5F), and horizontal
activity (Figure S5G). On the other hand, MPTP increased the rest
time (Figure S5D). Interestingly, NaPB significantly improved
MPTP-induced hypolocomotion (Figure S5A–G).
Figure 6. Activation of small G proteins (p21
ras and p21
rac) and NF-kB in ventral midbrain of MPTP-intoxicated mice is NaPB-
sensitive. A) Mice were treated with NaPB (200 mg/kg body wt/d) via gavage from 1 d prior to MPTP injection. Six h after the last injection of MPTP,
activation of p21
ras and p21
rac was monitored in ventral midbrain tissues. Experiment was repeated three times each time using two animal in each
group. B) Bands from three different mice were quantified and activation of p21
ras and p21
rac is shown as percent of control. C) Mice were treated
with NaPB (200 mg/kg body wt/d) from 3 h after the last injection of MPTP. Twenty-four h after the last injection of MPTP, ventral midbrain sections
were immunostained for p65 (low magnification). Midbrain sections of MPTP-intoxicated mice were also double-labeled for p65 and glial cell markers
(GFAP for astrocytes and CD11b for microglia). Results represent three independent experiments. D) NF-kB p65 positive cells counted in four nigral
sections (two images per slide) from each of four mice in an Olympus IX81 fluorescence microscope using the MicroSuite
TM imaging software are
mentioned as cells/mm
2.
ap,0.0001 vs saline-control;
bp,0.0001 vs MPTP.
doi:10.1371/journal.pone.0038113.g006
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ras Farnesylation and/or p21
rac
Geranylgeranylation Sufficient to Protect the
Nigrostriatum Against MPTP Toxicity?
In addition to inhibiting farnesylation of p21
ras and geranylger-
anylation of p21
rac, NaPB exhibits many other biological functions
including histone deacetylase (HDAC) inhibition [40], chemical
chaperoning upon endoplasmic reticulum (ER) stress [41] and
ammonia scavenging in urea cycle disorders [42], which could be
responsible for the protection of nigrostriatum from MPTP
neurotoxicity. Therefore, we investigated if inhibition of either
p21
ras or p21
rac alone was sufficient for the protection of the
nigrostriatum. MPTP-intoxicated mice received FTI and GGTI,
either separately at 10 mg/kg body wt/d or together at 5 mg/kg
body wt/d, via i.p. injection from 3 h after the last injection of
MPTP. After 7 d of MPTP intoxication, motor tasks were assayed
followed by monitoring the level of DA in the striatum. FTI and
GGTI, alone or in combination, were capable of improving
horizontal activity (Figure 9B), total distance traveled (Figure 9C),
number of movements (Figure 9D), and stereotypy time
Figure 7. Expression of proinflammatory molecules in ventral midbrain of MPTP-intoxicated mice is NaPB-sensitive. A) Mice were
treated with NaPB (200 mg/kg body wt/d) from 3 h after the last injection of MPTP. Twenty-four h after the last injection of MPTP, ventral midbrain
sections were immunostained for iNOS (low magnification). Midbrain sections of MPTP-intoxicated mice were also double-labeled for iNOS and glial
cell markers (GFAP for astrocytes and CD11b for microglia). Results represent three independent experiments. B) Cells positive for iNOS were counted
in four nigral sections (two images per slide) from each of four mice.
ap,0.0001 vs saline-control;
bp,0.0001 vs MPTP. The mRNA expression of TNF-a,
iNOS and IL-1b was analyzed by semi-quantitative RT-PCR (C) and quantitative real-time PCR (D). Data are means + SEM of five mice per group.
ap,0.0001 vs saline group;
bp,0.0001 vs the MPTP group.
doi:10.1371/journal.pone.0038113.g007
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in MPTP-intoxicated mice suggesting that suppression of either
p21
ras farnesylation or p21
rac geranylgeranylation alone is
sufficient for the protection of the nigrostriatum in MPTP-
intoxicated mice.
Does NaPB Halt the Disease Progression in a Chronic
MPTP Mouse Model?
While the acute MPTP model is helpful for quick drug
screening, elucidating molecular mechanisms and determining
the interaction between drug and MPTP, effects of acute
intoxication reverse over time. Therefore, recently a chronic
intoxicated model has been described [18,19], in which
significant loss of dopaminergic neurons is seen even six months
after MPTP intoxication. We examined if NaPB was capable of
protecting neurons in a chronic model (Figure 10A). As expected,
chronic MPTP intoxication led to marked loss of striatal
dopamine (Figure 10B) and decrease in horizontal activity
(Figure 10C), number of movements (Figure 10D), rearing
(Figure 10E), and stereotypy (Figure 10F–G). We initiated oral
NaPB treatment (100 mg/kg body wt/d) from the third injection
of MPTP/probenecid (Figure 10A). Consistent to that observed
in the acute model (Figure 8), NaPB, in this instance, also
significantly protected striatal DA (Figure 10B and improved
locomotor activities (Figure 10C–G).
Figure 8. NaPB protects dopaminergic neurons in MPTP-intoxicated mice. Mice receiving NaPB (200 mg/kg body wt/day) from 3 h after the
last injection of MPTP were sacrificed 7 d after the last injection of MPTP followed by TH immunostaining of SNpc (A) and striatum (B), counting of
TH-positive neurons in SNpc (C), quantification of TH-positive fibers in striatum (D), assay of neurotransmitters in striatum (E), and quantification of
GSH in nigra (F). Data are means + SEM of eight mice per group.
ap,0.0001 vs saline group;
bp,0.0001 vs the MPTP group.
doi:10.1371/journal.pone.0038113.g008
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Neuroinflammation and oxidative stress are two hallmarks of
neurodegenerative disorders. Therefore, identifying drugs to
attenuate the production of proinflammatory molecules and
ROS is an important area of research as such drugs may stop or
delay the progression of neurodegenerative disorders. Sodium
phenylbutyrate (NaPB) is a sodium salt of short chain fatty acid
having multiple clinical interests. Being known as BuphenylH or
triButyrateH in the US or AmmonapsH in Sweden, it is used as a
medication against urea cycle disorders involving deficiencies of
carbamylphosphate synthetase, ornithine transcarbamylase, or
argininosuccinic acid synthetase. Although its major function is to
scavenge ammonia and glutamine [42], recent studies have
described NaPB as a potent inhibitor of HDAC [40]. Due to its
HDAC inhibitory effects, it has been proposed as a drug against
various forms of cancer [43]. Accordingly, it has been also
clinically tested as an anticancer drug [44]. In addition to
ammonia removal and HDAC inhibition, Ozcan et al [41] have
shown that NaPB can also function as a chemical chaperon during
endoplasmic reticulum (ER) stress. Here we delineate two new
functions of NaPB. On one hand, NaPB inhibits the expression of
various proinflammatory molecules (iNOS, TNF-a and IL-1b)
from activated glial cells suggesting that NaPB is anti-inflamma-
tory. On the other, it suppresses the production of ROS from
Figure 9. FTI and GGTI protect DA and improve locomotor
activities in MPTP-intoxicated mice. Mice receiving FTI, GGTI or the
combination of the two via daily intraperitoneal injection from 3 h after
the last injection of MPTP were tested for motor functions (B, horizontal
activity; C, total distance; D, number of movement; E, stereotypy) 7 d
after the last injection of MPTP followed by measuring DA in striatum
(A). Data are means + SEM of eight mice per group.
ap,0.001 vs saline;
bp,0.001 vs MPTP;
cp,0.05 vs saline;
dp,0.05 vs MPTP.
doi:10.1371/journal.pone.0038113.g009
Figure 10. NaPB protects striatal dopamine and improves
motor functions in a chronic MPTP mouse model of PD. A) Six to
eight week old male C57BL/6 mice received 10 injections of MPTP (s.c.;
25 mg/kg body weight) together with 10 injections of probenecid (i.p.;
250 mg/kg body weight) for 5 weeks. Control group of mice received
only saline. One group of mice were treated with NaPB (100 mg/kg
body weight/d) via gavage from the 3
rd injection of MPTP/probenecid
and continued for 1 week thereafter. Mice were tested for different
motor tasks [horizontal activity (C), number of movements (D), rearing
(E), and stereotypy (F)] one week after the last injection of MPTP
followed by measuring the level of DA in striatum (B). Data are means +
SEM of eight mice per group.
ap,0.001 vs saline;
bp,0.001 vs MPTP;
cp,0.05 vs saline;
dp,0.05 vs MPTP.
doi:10.1371/journal.pone.0038113.g010
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antioxidant activities.
The signaling events required for the transcription of iNOS and
proinflammatory cytokines are becoming clear. Although many
transcription factors such as NF-kB, C/EBPb, AP-1, STAT, IRF-
1 etc play a role, activation of NF-kB seems essential for the
transcription of most of the proinflammatory molecules
[8,9,24,25,26,45]. Therefore, for a drug to exhibit an anti-
inflammatory effect, it is almost mandatory to attenuate the
activation of NF-kB. Accordingly, NaPB inhibits the activation of
NF-kB at both DNA-binding and transcriptional levels. However,
it was unknown by which mechanisms NaPB suppressed the
activation of NF-kB. p21
ras is a membrane-associated small
guanine nucleotide-binding protein that plays a central role in
transmitting many extracellular signals within the cell [46,47].
Here we present evidence that NaPB suppressed the activation of
p21
ras and thereby inhibited the activation of NF-kB in microglia.
Our conclusion is based on the following observations: First, NaPB
reduced the level of cholesterol in vivo in mice at a level comparable
to pravastatin suggesting that this drug may be used to lower
cholesterol in patients with hypercholesterolemia. However,
HMG-CoA, mevalonate, GGPP, and FPP, but not cholesterol,
reversed the inhibitory effect of NaPB on the activation of NF-kB
suggesting that depletion of intermediates, but not end products, of
the mevalonate pathway is involved in the anti-inflammatory effect
of NaPB. Second, FTI, capable of inhibiting farnesylation of p21
ras,
and GGTI, capable of inhibiting geranylgeranylation of p21
rac,
inhibited the activation of NF-kB, suggesting the involvement of
both p21
ras and p21
rac in LPS-induced microglial activation of
NF-kB. Third, NaPB inhibited the activation of both p21
ras and
p21
rac in LPS-stimulated microglial cells. These small G proteins
function by binding to the cytoplasmic surface of the plasma
membrane. This membrane localization involves isoprenylation of
small G proteins at the C-terminus [46]. Our results suggest that
NaPB attenuates farnesylation of p21
ras and geranylgeranylation
of p21
rac and thereby inhibits the signal transmission to the
downstream signaling molecules [46,47]. Although here we
demonstrate that NaPB inhibits the phosphorylation of IkBa
thereby attenuating the activation of NF-kB, p65 is known to be
acetylated by histone acetyl transferases (HAT) [48]. Therefore,
being an inhibitor of HDAC, NaPB may also inhibit the
acetylation of p65 and suppress its transcriptional activity.
Although there are many ROS-producing molecules, recent
studies identify NADPH oxidase as the most important ROS
producer in response to various inflammatory and degenerative
stimuli. NADPH oxidase is a five-subunit protein that generates
superoxide from molecular oxygen and is composed of two
membrane-bound subunits, gp91
phox and p22
phox, and at least two
cytosolic subunits, p47
phox and p67
phox. During its activation,
p21
rac comes into the picture, associates with p67
phox and gp91
phox
and completes the formation of the active enzyme complex [3].
Then this active NADPH oxidase catalyzes the formation of
superoxide from molecular oxygen. Here, we demonstrate that
NaPB suppressed the activation of p21
rac and thereby reduced the
production of ROS from activated microglia. Our conclusion is
based on the following observations: First, HMG-CoA, mevalonate
and GGPP, but not FPP, reversed the inhibitory effect of NaPB on
superoxide, suggesting that geranylgeranylation, but not farnesyla-
tion, is involved in the antioxidant effect of NaPB. Second, GGTI,
but not FTI, inhibited the production of superoxide from activated
microglia. Because GGTI inhibits geranylgeranylation of p21
rac,
these results suggest that p21
rac, but not p21
ras, may be involved in
LPS-induced microglial production of superoxide. Third, a
dominant-negative mutant of p21
rac (Dp21
rac), but not p21
ras
(Dp21
ras), knocked down microglial production of superoxide.
Fourth, NaPB inhibited the activation of p21
rac in LPS-stimulated
microglial cells. Similar to p21
ras, p21
rac also requires isoprenyla-
tion for attachment to plasma membrane. However, in contrast to
farnesylation of p21
ras, p21
rac requires geranylgeranylation for
membrane attachment and activation. Our results suggest that
NaPB suppresses geranylgeranylation of p21
rac and thereby
inhibits its assembly with the NADPH oxidase complex.
The MPTP mouse model is particularly useful in testing new
therapeutic intervention in PD. Because NaPB inhibits the
production of proinflammatory molecules and ROS, hallmarks
of neurodegenerative pathology, we decided to investigate the
efficacy of NaPB in protecting nigrostriatal neurons in the MPTP
mouse model of PD. Several lines of evidence presented in this
manuscript clearly establish that NaPB is capable of protecting
dopaminergic neurons from Parkinsonian toxicity. When this
manuscript was in preparation, Zhou et al [49] have shown that
NaPB upregulates DJ-1 in neurons and protects dopaminergic
neurons in MPTP mouse model. However, here we have
demonstrated that NaPB is capable of suppressing glial activation
and reducing the production of proinflammatory molecules and
ROS in activated glial cells and in vivo in the SNpc of MPTP-
intoxicated mice via modulation of small G proteins.
There are several advantages of NaPB over other proposed anti-
neurodegenerative therapies. First, NaPB is fairly nontoxic. It is an
FDA-approved drug against urea cycle disorders in children.
Second, NaPB can be taken orally, the least painful route. Here we
have shown that oral administration of NaPB protects the
nigrostriatum in both acute and chronic MPTP models of PD.
Third, although here we have not tested, NaPB being a lipophilic
molecule is most likely able to diffuse through the blood-brain
barrier. For example, glutamine toxicity is a problem in urea cycle
disorders. After treatment of patients with urea cycle disorders,
NaPB is known to combine with glutamine to produce
phenylacetylglutamine, a compound that is readily excreted in
the urine. Simultaneous serum and CSF sampling in those patients
showed comparable levels of phenylacetylglutamine in the CSF
[50], suggesting that NaPB is capable of crossing the BBB.
In summary, we have demonstrated that NaPB inhibits glial
activation of NF-kB by suppressing p21
ras activation and that
NaPB attenuates ROS production by suppressing p21
rac activa-
tion. Because NaPB suppresses the mevalonate pathway, it is also
able to lower cholesterol in vivo in mice at a level comparable to
pravastatin, a cholesterol-lowering drug, suggesting that NaPB
may be a choice of cholesterol-lowering drug in cases where statins
exhibit toxicity. We also demonstrate that NaPB suppresses the
activation of p21
ras and p21
rac and blocks the activation of NF-kB
in the SNpc, inhibits nigral expression of proinflammatory
molecules and the of activation glial cells, increases the level
antioxidant GSH in the SNpc, protects the loss of dopaminergic
neurons, and improves the behavioral functions in MPTP-
intoxicated mice. These results highlight undiscovered properties
of NaPB and indicate that NaPB may be used for therapeutic
intervention in PD or neurodegenerative disorders.
Supporting Information
Figure S1 Effect of NaPB on serum level of cholesterol
in male C57/BL6 mice. Mice (6–8 wk old) were treated with
NaPB(200 mg/kg body wt/d) and pravastatin (1 mg/kgbodywt/d)
separatelyviagavagefor7 dfollowedbyquantificationofcholesterol
in serum using a simple fluorometric method. Results represent
mean + SD of five mice per group (n=5).
ap,0.05 vs control.
(TIF)
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+-induced expression of
proinflammatory molecules in mouse microglial cells.
Mouse BV-2 microglial cells were treated with different concen-
trations of NaPB for 6 h followed by stimulation with 1 mM MPP
+
under serum-free condition. After 5 h of stimulation, the mRNA
expression of iNOS, IL-1b and TNF-a was monitored by semi-
quantitative RT-PCR (A) and quantitative real-time PCR (C,
iNOS; D, IL-1b; E, TNF-a). After 24 h of stimulation, the protein
expression of iNOS was monitored by Western blot (B). Results
are mean + SD of three different experiments.
ap,0.001 vs
control;
bp,0.001 vs MPP
+.
(TIF)
Figure S3 Time course of nigral activation of p21
ras and
expression of iNOS and striatal loss of dopamine in
MPTP-intoxicated mice. A) Mice were treated with NaPB
(200 mg/kg body wt/d) via gavage from 1 d prior to MPTP
injection. At different h of MPTP insult, nigral punches from two
mice were pooled together and analyzed for the activation of
p21
ras (A) and the expression of iNOS mRNA (B, RT-PCR; C,
real-time PCR). Experiments were repeated three times each time
using two animals in each group.
ap,0.001 vs control (0h)-iNOS. D)
At different days of MPTP insult, dopamine was quantified in
striata. Data are means + SEM of six mice per group.
*p,0.05 vs
control;
**p,0.001 vs control.
(TIF)
Figure S4 Increased expression of CD11b and GFAP in
ventral midbrain of MPTP-intoxicated mice is NaPB-
sensitive. A) Mice were treated with NaPB (200 mg/kg body
wt/d) from 3 h after the last injection of MPTP. Twenty-four h
after the last injection of MPTP, ventral midbrain sections were
immunostained for GFAP and CD11b. Results represent analyses
of four nigral sections (two images per slide) from each of four
mice. The mRNA expression of GFAP and CD11b was analyzed
by semi-quantitative RT-PCR (B) and quantitative real-time PCR
(C). Data are means + SEM of five mice per group.
ap,0.0001 vs
saline group;
bp,0.0001 vs the MPTP group.
(TIF)
Figure S5 NaPB improves motor functions in MPTP-
intoxicated mice. Mice receiving NaPB (200 mg/kg body wt/
day) from 3 h after the last injection of MPTP were tested for
motor functions (A, rotorod; B, movement time; C, total distance;
D, rest time; E, stereotypy counts; F, rearing; G, horizontal
activity) 7 d after the last injection of MPTP. Data are means +
SEM of eight mice per group.
ap,0.001 vs MPTP;
bp,0.05 vs
MPTP.
(TIF)
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